ATE365051T1 - Stabilisierung von rapamycinen oder rapamycinderivaten - Google Patents

Stabilisierung von rapamycinen oder rapamycinderivaten

Info

Publication number
ATE365051T1
ATE365051T1 AT99959381T AT99959381T ATE365051T1 AT E365051 T1 ATE365051 T1 AT E365051T1 AT 99959381 T AT99959381 T AT 99959381T AT 99959381 T AT99959381 T AT 99959381T AT E365051 T1 ATE365051 T1 AT E365051T1
Authority
AT
Austria
Prior art keywords
rapamycins
stabilization
rapamycin derivatives
rapamycin
derivatives
Prior art date
Application number
AT99959381T
Other languages
German (de)
English (en)
Inventor
Francois Navarro
Samuel Petit
Guy Stone
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE365051(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE365051T1 publication Critical patent/ATE365051T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
AT99959381T 1998-12-07 1999-12-06 Stabilisierung von rapamycinen oder rapamycinderivaten ATE365051T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9826882.4A GB9826882D0 (en) 1998-12-07 1998-12-07 Organic compounds
GBGB9904934.8A GB9904934D0 (en) 1998-12-07 1999-03-04 Organic compounds

Publications (1)

Publication Number Publication Date
ATE365051T1 true ATE365051T1 (de) 2007-07-15

Family

ID=26314797

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99959381T ATE365051T1 (de) 1998-12-07 1999-12-06 Stabilisierung von rapamycinen oder rapamycinderivaten

Country Status (38)

Country Link
US (5) US6605613B2 (enExample)
EP (4) EP1743657A3 (enExample)
JP (3) JP3805625B2 (enExample)
KR (2) KR100695834B1 (enExample)
CN (2) CN1876657B (enExample)
AR (3) AR026102A1 (enExample)
AT (1) ATE365051T1 (enExample)
AU (1) AU759219B2 (enExample)
BE (1) BE1012869A3 (enExample)
BR (1) BR9915986A (enExample)
CA (3) CA2732620C (enExample)
CO (1) CO4980847A1 (enExample)
CY (1) CY1106870T1 (enExample)
CZ (2) CZ302210B6 (enExample)
DE (1) DE69936352T3 (enExample)
DK (1) DK1137439T4 (enExample)
ES (1) ES2288033T5 (enExample)
FR (1) FR2786771B1 (enExample)
GB (2) GB9826882D0 (enExample)
HK (1) HK1038889B (enExample)
HU (2) HU230174B1 (enExample)
ID (1) ID29250A (enExample)
IL (1) IL143092A0 (enExample)
IT (1) IT1319701B1 (enExample)
MY (2) MY127579A (enExample)
NO (2) NO332698B1 (enExample)
NZ (2) NZ511936A (enExample)
PE (1) PE20001333A1 (enExample)
PL (2) PL208854B1 (enExample)
PT (1) PT1137439E (enExample)
RU (1) RU2243769C2 (enExample)
SG (1) SG151072A1 (enExample)
SI (1) SI1137439T2 (enExample)
SK (2) SK286688B6 (enExample)
TR (2) TR200101416T2 (enExample)
TW (2) TWI270550B (enExample)
WO (1) WO2000033878A2 (enExample)
ZA (1) ZA200104360B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
AU2003213024A1 (en) 2002-02-13 2003-09-04 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Method for extracting a macrolide from biomatter
AR040693A1 (es) 2002-07-30 2005-04-13 Wyeth Corp Formulaciones parenterales
TR200500302T3 (tr) * 2003-03-31 2005-04-21 Biogal Gyogyszergyar Rt. Makrolidlerin kristalizasyonu ve saflaştırılması.
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
CA2533548C (en) 2003-07-24 2010-02-16 Teva Gyogyszergyar Reszvenytarsasag Method of purifying macrolides
CN1882338A (zh) 2003-09-18 2006-12-20 马库赛特公司 经巩膜递送
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
EP1703938A1 (en) * 2003-12-10 2006-09-27 Acrux DDS Pty Ltd Method of treatment for undesired effect following transdermal or topical drug delivery
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
CN101076319A (zh) * 2004-09-29 2007-11-21 科迪斯公司 稳定的非晶形雷帕霉素样化合物的药物剂型
WO2006086750A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Liquid formulations for treatment of diseases or conditions
WO2007067566A2 (en) * 2005-12-07 2007-06-14 Wyeth Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
EP1962819A1 (en) * 2005-12-20 2008-09-03 Wyeth Control of cci-779 dosage form stability through control of drug substance impurities
CA2635797C (en) 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
WO2007112052A2 (en) 2006-03-23 2007-10-04 Macusight, Inc. Formulations and methods for vascular permeability-related diseases or conditions
WO2011151704A2 (en) 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
US20120165260A2 (en) * 2010-06-07 2012-06-28 Telik, Inc. Crystalline ezatiostat hydrochloride ansolvate
WO2012017449A1 (en) * 2010-08-04 2012-02-09 Meril Life Sciences Pvt. Ltd Process for preparation of novel 42-0-(heteroalkoxyalkyl) rapamycin compounds with anti-proliferative properties"
ES2753529T3 (es) 2010-11-19 2020-04-13 Biocon Ltd Procesos para la preparación de everolimús y productos intermedios del mismo
CA2838387A1 (en) 2011-06-06 2012-12-13 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
WO2013022201A1 (en) * 2011-08-11 2013-02-14 Dong-A Pharm. Co., Ltd. Process of preparing a stabilized and solubilized formulation of sirolimus derivatives
US9610385B2 (en) 2013-03-07 2017-04-04 Abbott Cardiovascular Systems Inc. Method of fabricating an implantable medical device comprising a rapamycin derivative
IN2013MU02532A (enExample) 2013-07-31 2015-06-26 Sahajanand Medical Technologies Pvt Ltd
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
CN104892632B (zh) * 2015-06-03 2017-12-26 道中道（菏泽）制药有限公司 一种晶体形式的依维莫司及其制备方法
EP3329916A4 (en) 2015-07-28 2019-03-20 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION COMPRISING RAPAMYCIN OR A DERIVATIVE THEREOF, AND PROCESS FOR PRODUCING THE SAME
WO2017038612A1 (ja) * 2015-08-28 2017-03-09 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
WO2017047618A1 (ja) * 2015-09-18 2017-03-23 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
JP6855470B2 (ja) 2016-05-27 2021-04-07 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
KR102051806B1 (ko) * 2018-01-12 2019-12-04 주식회사 종근당 에베로리무스를 포함하는 안정화된 약제학적 제제
US11814397B2 (en) 2020-03-27 2023-11-14 Boston Scientific Scimed, Inc. Methods for crystallization of drugs
JP2023028473A (ja) * 2021-08-19 2023-03-03 日本マイクロバイオファーマ株式会社 エベロリムスの製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3996355A (en) 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
US4049128A (en) 1976-11-18 1977-09-20 Westinghouse Air Brake Company Control system for automatic railway car coupler
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
JPH01249651A (ja) † 1988-02-18 1989-10-04 E I Du Pont De Nemours & Co セラミツク／蒸留可能な結合剤組成物
GB8803836D0 (en) 1988-02-18 1988-03-16 Glaxo Group Ltd Compositions
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
FI97472C (fi) 1991-05-07 1996-12-27 American Home Prod Menetelmä terapeuttisesti käyttökelpoisten rapamysiinijohdannaisten valmistamiseksi anti-inflammatorisina ja antifungaalisina aineina
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
ES2258763T3 (es) 1992-10-13 2006-09-01 Wyeth Carbamatos de rapamicina.
RU2181054C2 (ru) * 1994-11-02 2002-04-10 Новартис Аг Микроэмульсионный предконцентрат
DK0833828T3 (da) * 1995-06-09 2003-03-17 Novartis Ag Rapamycinderivater
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
PT956034E (pt) * 1996-07-30 2002-12-31 Novartis Ag Composicoes farmaceuticas para o tratamento da rejeicao de transplantes estados inflamatorios ou auto-imunes compreendendo ciclosporina a e 40-o-(2-hidroxietil)-rapamicina
US6362264B1 (en) * 1996-12-20 2002-03-26 Ck Witco Corporation Stabilizer for food contact and medical grade PVC
AU6041498A (en) 1997-02-04 1998-08-25 Abbott Laboratories Pain reducing parenteral liposome formulation

Also Published As

Publication number Publication date
JP3805625B2 (ja) 2006-08-02
PL196627B1 (pl) 2008-01-31
AR054444A2 (es) 2007-06-27
AR048073A2 (es) 2006-03-29
SK286688B6 (sk) 2009-03-05
JP2006111637A (ja) 2006-04-27
SG151072A1 (en) 2009-06-29
CY1106870T1 (el) 2012-09-26
DK1137439T3 (da) 2007-09-10
CA2651609A1 (en) 2000-06-15
TR200101416T2 (tr) 2002-01-21
CA2351580A1 (en) 2000-06-15
GB9826882D0 (en) 1999-01-27
KR20010101128A (ko) 2001-11-14
ES2288033T3 (es) 2007-12-16
NO20121113L (no) 2001-05-16
DE69936352T3 (de) 2012-05-03
BE1012869A3 (fr) 2001-04-03
CN1261163C (zh) 2006-06-28
TR200201428T2 (tr) 2002-12-23
GB9904934D0 (en) 1999-04-28
JP2002531527A (ja) 2002-09-24
SK7662001A3 (en) 2001-12-03
DE69936352T2 (de) 2008-02-14
CZ302210B6 (cs) 2010-12-22
NO332698B1 (no) 2012-12-10
BR9915986A (pt) 2001-09-04
AU759219B2 (en) 2003-04-10
CN1876657A (zh) 2006-12-13
US7572804B2 (en) 2009-08-11
EP1743657A2 (en) 2007-01-17
MY120594A (en) 2005-11-30
NZ511936A (en) 2003-10-31
HK1038889B (en) 2008-01-25
JP2005200429A (ja) 2005-07-28
NZ527781A (en) 2004-11-26
EP1743657A3 (en) 2007-03-28
US20080161334A1 (en) 2008-07-03
US6852729B2 (en) 2005-02-08
JP5165199B2 (ja) 2013-03-21
ID29250A (id) 2001-08-16
NO334612B1 (no) 2014-04-22
CA2732620C (en) 2013-08-06
CA2732620A1 (en) 2000-06-15
TW200540179A (en) 2005-12-16
PL348333A1 (en) 2002-05-20
MY127579A (en) 2006-12-29
HUP0104489A3 (en) 2004-05-28
HUP0104489A2 (hu) 2002-03-28
PT1137439E (pt) 2007-09-25
SI1137439T1 (sl) 2008-06-30
EP2279751A2 (en) 2011-02-02
EP2269651A2 (en) 2011-01-05
US7297703B2 (en) 2007-11-20
PL208854B1 (pl) 2011-06-30
NO20012424L (no) 2001-05-16
US7741338B2 (en) 2010-06-22
ITMI992520A1 (it) 2001-06-02
CA2351580C (en) 2012-03-20
IT1319701B1 (it) 2003-10-27
EP1137439A2 (en) 2001-10-04
US20020032213A1 (en) 2002-03-14
US20050107418A1 (en) 2005-05-19
CZ20012001A3 (cs) 2001-09-12
EP2279751A3 (en) 2011-02-16
HU228939B1 (en) 2013-07-29
JP5043308B2 (ja) 2012-10-10
HK1038889A1 (en) 2002-04-04
FR2786771A1 (fr) 2000-06-09
CZ303006B6 (cs) 2012-02-22
EP1137439B1 (en) 2007-06-20
FR2786771B1 (fr) 2002-12-27
US20090270441A1 (en) 2009-10-29
WO2000033878A2 (en) 2000-06-15
HU230174B1 (hu) 2015-09-28
TWI270550B (en) 2007-01-11
KR20060096477A (ko) 2006-09-11
DK1137439T4 (da) 2012-03-19
AU1657300A (en) 2000-06-26
CN1876657B (zh) 2013-01-09
ZA200104360B (en) 2002-01-16
TWI248938B (en) 2006-02-11
DE69936352D1 (de) 2007-08-02
KR100695834B1 (ko) 2007-03-19
US6605613B2 (en) 2003-08-12
ITMI992520A0 (it) 1999-12-02
EP2269651A3 (en) 2011-03-09
PE20001333A1 (es) 2000-12-12
CN1374872A (zh) 2002-10-16
NO20012424D0 (no) 2001-05-16
SK287325B6 (sk) 2010-07-07
AR026102A1 (es) 2003-01-29
RU2243769C2 (ru) 2005-01-10
US20030191148A1 (en) 2003-10-09
ES2288033T5 (es) 2012-04-10
IL143092A0 (en) 2002-04-21
CO4980847A1 (es) 2000-11-27
WO2000033878A3 (en) 2000-11-02
SI1137439T2 (sl) 2012-05-31
EP1137439B2 (en) 2011-11-23

Similar Documents

Publication Publication Date Title
ATE365051T1 (de) Stabilisierung von rapamycinen oder rapamycinderivaten
FI962487L (fi) Rapamysiinijohdannaisia
ATE222256T1 (de) Polymorphe form von clopidogrel-hydrogenosulfat
ID29021A (id) Komposisi galantamina pelepasan terkontrol
DK1384478T3 (da) Antibiotiske sammensætninger indeholdende moxifloxacin til behandling af øjet
ATE228135T1 (de) Rapamycinderivate
PT945132E (pt) Composicao de ibuprofeno
PT1032396E (pt) Esterilizacao de glucocorticoesteroides
DE60028307D1 (de) Eliminierung von interferenzsignalen
DE50010774D1 (de) Anlage zur bearbeitung von wafern
LV12167A (lv) Jauni makrocikliski savienojumi ka metalproteinazes inhibitori
PT1100326E (pt) Microcapsulas de libertacao activada por bases
DE50013866D1 (de) Anlage zur bearbeitung von wafern
DE69903143D1 (de) Chromanon und thiochromanon derivate
PT869121E (pt) Derivados de propanolamina hipolipidemicos
PT1140924E (pt) Derivados de piperazina
PT1237856E (pt) Novos derivados fenilicos tri-substituidos e analogos
DE69806558D1 (de) Stabilisierung von 3-Isothiazolonlösungen
NO20010456D0 (no) Triazolopyridiner for behandling av trombose-problemer
DE60000343D1 (de) Stabilisierung von isothiazolonen
ID28032A (id) TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2
PT1178984E (pt) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinilamimometilcromano
DE69909592D1 (de) Verwendung von thiadiazolo[4,3-a]pyridine derivaten
NO20003529D0 (no) Behandling av dyskinesi
DE50012862D1 (de) Anlage zur bearbeitung von wafern

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1137439

Country of ref document: EP